6 news items
Alnylam Issues 2023 Corporate Responsibility Report
ALNY
7 May 24
transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
ALNY
2 May 24
benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
.
"We are delighted to extend yet again our existing partnership with Medison, which will enable us to enhance our presence and bring the benefits
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
the benefits of Alnylam's innovative RNAi therapeutics to patients in additional APAC and LATAM markets," said Norton Oliveira, Senior Vice-President
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
ALNY
7 Apr 24
diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech
y7boiqaxl6do tmztpyh4gwaby1wbtx5
ALNY
20 Mar 24
in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting
- Prev
- 1
- Next